title: Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
abstract: OBJECTIVE
  Recent studies have shown that a BRAF(V600E) reflects poor prognosis, mainly in Western countries. However, some clinicians in Japan have suggested that the BRAF(V600E) mutation is not associated with a poor prognosis. Therefore, we investigated a relationship between BRAF(V600E) mutation and clinicopathologic factors.
  
  
  METHODS
  From September 2008 to December 2009, we performed routine analysis of the BRAF(V600E) mutation using thyroid cancer tissue from 424 patients who underwent thyroidectomy with cervical lymph node dissection.
  
  
  RESULTS
  The BRAF(V600E) mutation was found in 335 of 424 cases (79%) and was higher in classic papillary thyroid carcinoma (PTC) (79.7%) than in the follicular variant of PTC (62.5%) (P = .019). On univariate analysis, the BRAF(V600E) mutation was associated with extrathyroidal extension (P = .009) and variants of PTC (P = .019), but a high-risk Metastasis, Patient Age, Completeness of resection, local Invasion and Tumor Size (MACIS) score (≥ 6) (P = .146) and lymph node metastasis (P = .628) were not significantly associated with the BRAF(V600E) mutation. Multivariate analysis showed that extrathyroidal extension is independently associated with the BRAF(V600E) mutation (relative ratio: 2.466; 95% confidence interval, 1.213-5.011; P < .013).
  
  
  CONCLUSIONS
  It is not clear that the BRAF(V600E) mutation is useful for prediction of poor prognosis of PTC.
authors.affiliation: Department of Surgery, Hospital Pathology, Catholic University of Korea, Seoul, Korea.
authors.forename: Jung Kwang
authors.initials: JK
authors.lastname: Nam
authors.forename: Chan Kwon
authors.initials: CK
authors.lastname: Jung
authors.forename: Byung Joo
authors.initials: BJ
authors.lastname: Song
authors.forename: Dong Jun
authors.initials: DJ
authors.lastname: Lim
authors.forename: Byung Joo
authors.initials: BJ
authors.lastname: Chae
authors.forename: Nam Seop
authors.initials: NS
authors.lastname: Lee
authors.forename: Woo Chan
authors.initials: WC
authors.lastname: Park
authors.forename: Jeong Soo
authors.initials: JS
authors.lastname: Kim
authors.forename: Sang Seol
authors.initials: SS
authors.lastname: Jung
authors.forename: Ja Seong
authors.initials: JS
authors.lastname: Bae
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001707:Biopsy, Needle; D002277:Carcinoma; D002291:Carcinoma, Papillary; D015331:Cohort Studies; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007723:Korea; D008198:Lymph Nodes / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D017354:Point Mutation; D011237:Predictive Value of Tests; D011300:Preoperative Care / Q000379:methods; D011379:Prognosis; D016016:Proportional Hazards Models; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics* / Q000378:metabolism; D012680:Sensitivity and Specificity; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D013965:Thyroidectomy / Q000379:methods; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf